Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Equity Ratio (2016 - 2025)

UroGen Pharma (URGN) has disclosed Equity Ratio for 10 consecutive years, with 0.53 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 1607.75% year-over-year to 0.53, compared with a TTM value of 0.53 through Dec 2025, down 1607.75%, and an annual FY2025 reading of 0.53, down 1607.75% over the prior year.
  • Equity Ratio was 0.53 for Q4 2025 at UroGen Pharma, up from 0.62 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.79 in Q1 2021 and bottomed at 1.45 in Q2 2023.
  • Average Equity Ratio over 5 years is 0.25, with a median of 0.21 recorded in 2023.
  • The sharpest move saw Equity Ratio soared 138.96% in 2024, then tumbled 1607.75% in 2025.
  • Year by year, Equity Ratio stood at 0.07 in 2021, then plummeted by 1037.86% to 0.66 in 2022, then skyrocketed by 44.5% to 0.37 in 2023, then skyrocketed by 91.58% to 0.03 in 2024, then crashed by 1607.75% to 0.53 in 2025.
  • Business Quant data shows Equity Ratio for URGN at 0.53 in Q4 2025, 0.62 in Q3 2025, and 0.45 in Q2 2025.